Paul Yang MD PhD
Cataract Related, Retinal Disease, Uveitis
Associate Professor, Ophthalmic Genetics & Ocular Immunology
Join to View Full Profile
545 SW Campus DrPortland, OR 97239
Phone+1 503-494-8311
Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Oregon Health Science University HospitalFellowship, Ophthalmic Genetics and Inherited Retinal Degeneration, 2012 - 2013
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Ocular Immunology/Uveitis, 2011 - 2012
University of Utah HealthFellowship, Surgical Retina and Vitreous, 2010 - 2011- University of Utah HealthResidency, Ophthalmology, 2007 - 2008
- University of Utah HealthInternship, Internal Medicine, 2006 - 2007
Geisel School of Medicine at DartmouthClass of 2006
DartmouthPhD, Neurophysiology , 1998 - 2003
Certifications & Licensure
OR State Medical License 2012 - 2025
MA State Medical License 2011 - 2015
UT State Medical License 2007 - 2014
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) Start of enrollment: 2015 May 01
Publications & Presentations
PubMed
- Evolution of vitelliform maculopathy in a pediatric patient with a homozygousvariant.Alessia Amato, Paul Yang
American Journal of Ophthalmology Case Reports. 2025-06-01 - Variants in CFAP410 cause a range of retinal and skeletal phenotypes.Ryan E Schmidt, Amy E Pohodich, David Birch, Kaylie Jones, Byron L Lam
NPJ Genomic Medicine. 2025-04-17 - Effects of medications on the human electroretinogram: A comprehensive review.Justin J Grassmeyer, Mark E Pennesi, Paul Yang, Wayne Tschetter, Lesley A Everett
Survey of Ophthalmology. 2025-04-12
Press Mentions
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt DiseaseMarch 14th, 2025- SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt DiseaseDecember 12th, 2024
- Gene Therapy Allows Teen to See Snowflakes for the First TimeApril 5th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
